Investigating how a specific protein affects alcohol consumption and its potential as a treatment target for alcohol use disorder.
Gsk3b in ethanol consumption and as a therapeutic target for alcohol use disorder
['FUNDING_R01'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-10647812
This study is looking at how a specific protein in the brain, called GSK3B, affects drinking habits and how it changes when someone drinks alcohol, with the goal of finding new ways to help people who struggle with alcohol use.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-10647812 on ClinicalTrials.gov |
What this research studies
This research explores the role of glycogen synthase kinase-3 beta (GSK3B) in regulating how much alcohol is consumed. It examines how GSK3B is affected by alcohol exposure and how this protein might influence behaviors related to alcohol use. The study involves detailed analysis of brain circuits and cellular mechanisms in animal models to understand how GSK3B can be targeted to reduce alcohol consumption. By using advanced genetic and pharmacological techniques, the research aims to uncover the pathways that could lead to new treatments for alcohol use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with alcohol use disorder or those who consume alcohol excessively.
Not a fit: Patients who do not consume alcohol or have no history of alcohol use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for individuals struggling with alcohol use disorder.
How similar studies have performed: Previous studies have shown promising results in targeting GSK3B for behavioral modulation, indicating potential for success in this approach.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MILES, MICHAEL F — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: MILES, MICHAEL F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.